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A SKEW NORMAL MODEL OF THE DOSE-EFFECT RELATION
IN PHARMACOLOGY
FRANCIS LAVERGNE AND NICOLAS MARIE
Abstract. This paper deals with a skew-normal model of the relation be-
tween a dose d > 0 and a quantitative measure E(d) of an effect of the ad-
ministered drug. Precisely, E(d) is a measure of the therapeutic response or a
measure of a side-effect. Some existing and additional properties of the logis-
tic functions are proved, and a skew-normal model of the escape time of rats
under an experimental antidepressant medication is provided.
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1. Introduction
This paper deals with a skew-normal model of the relation between a dose d > 0
and a quantitative measure E(d) of an effect of the administered drug. Precisely,
E(d) is a measure of the therapeutic response or a measure of a side-effect.
As explained in Prentice [10] and Brown [4], it is usual to put
E(d) :=
∫ (d−µ)/σ
0
f(x)dx
where, µ ∈ R, σ > 0 and f : R → R is a probability density function. Often, f
is a probit or a logit function. The parameters µ and σ are estimated from the
observations. For an application on clinical datas, for instance, see Verlato et al.
[11].
The skew-normal distribution has been already used to model the quantal response.
In [12], Section 3.5, Wagner assumes that f is a skew-normal density function. On
the skew-normal distribution, see Azzalini [2] and Chen et al. [5]. The basics on
the skew-normal distribution are stated at Section 3.1. On the multidimensional
1
ar
X
iv
:1
50
4.
04
25
9v
1 
 [s
tat
.M
E]
  1
6 A
pr
 20
15
2 FRANCIS LAVERGNE AND NICOLAS MARIE
skew-normal distributions and an application in neurotoxicology, see T. Baghfalaki
et al. [3].
The model studied in this paper is a family of random variables E := {E(d), d ∈ R+}
satisfying the following conditions :
(1) For every d ∈ R+, E(d)  N (ξ(d), ω2(d), α(d)) where ξ, α ∈ C0(R+,R)
and ω ∈ C0(R+, ]0,∞[).
(2) µ : d ∈ R+ 7−→ E[E(d)] is a logistic function.
(3) There exists d0 ∈ R+ such that σ : d ∈ R+ 7−→
√
var[E(d)] is decreasing
on [d0,∞[, and
lim
d→∞
σ(d) = 0.
Assume that E(d) is a measure of the therapeutic response of the administered drug
at the dose d ∈ R+. It is usual to assume that E(d) is a Gaussian random variable.
The skewness of the empirical distributions are taken into account in the model E
of the therapeutic response in order to refine the choice of an optimal dose. Indeed,
the skewness of the distribution of E(d) indicates if the therapeutic responses of the
major part of the patients are over (positive skewness coefficient) or under (nega-
tive skewness coefficient) the mean therapeutic response. Therefore, if the mean of
E(d) is high enough, its skewness coefficient is positive and its standard deviation
is small enough, then the dose d is admissible. In fact, ideally, the optimal dose
should maximise the mean and the skewness coefficient, and minimize the standard
deviation of the therapeutic response.
Section 2 deals with some existing and additional properties of the logistic func-
tions. Section 2 provides an approximation method of the parameters of the logistic
functions in the most general case, which is used at Section 4. The proofs of the
results stated at Section 2 are detailed at Appendix A.
Section 3 deals with the estimation of the functions µ and σ, and then of the
functions ξ, ω and α. So, for each admissible dose d > 0, the model E allows to
simulate the measure of the effect E(d) multiple times for a better evaluation at the
dose d. As mentioned above, the basics on the skew-normal distribution are stated
at Section 3.1.
Section 4 deals with a model of the escape time of rats under an experimental an-
tidepressant medication. In psychopharmacology, since the medications are often
administered for several months or years, it is crucial to find the smallest efficient
dose. See Lavergne and Jay [8] about the efficiency of antidepressant medications
for small doses.
In [7], Holford and Sheiner studied the relationship between the therapeutic re-
sponse and the elimination process of the drug. In a forthcoming work, the dose-
effect model studied in this paper will be related to the fractional pharmacokinetics
model studied in Marie [9].
2. Approximation of the parameters of the logistic functions
This section deals with some existing and additional properties of the logistic
functions.
Consider n ∈ N∗ observations y1, . . . , yn > 0 of a logistic function f at x1, . . . , xn
respectively. Many authors approximate the parameters of the function f by linear
A SKEW NORMAL MODEL OF THE DOSE-EFFECT RELATION IN PHARMACOLOGY 3
regression on (x1, z1), . . . , (xn, zn), where
zi := log
[(
yi
y∗
)−1
− 1
]
; ∀i ∈ {1, . . . , n}
and
y∗ := max
i∈{1,...,n}
yi.
The major drawback of that method is to assume that
lim
x→−∞ f(x) = y
∗ or lim
x→∞ f(x) = y
∗.
This section provides an approximation method of the parameters of the logistic
functions in the most general case, which is used at Section 4. The proofs of the
results stated in this section are detailed at Appendix A.
Definition 2.1. f : R→ R is a logistic function if and only if,
f(x) := l1 +
1
(l2 − l1)−1 + emx+p ; ∀x ∈ R
with m ∈ R∗, p ∈ R, and l1, l2 ∈ R such that l2 > l1.
Throughout this section, f is the logistic function defined at Definition 2.1.
Proposition 2.2. The logistic function f satisfies the following properties :
(1) If m < 0 (resp. m > 0), then
lim
x→−∞ f(x) = l1 and limx→∞ f(x) = l2 (resp. limx→−∞ f(x) = l2 and limx→∞ f(x) = l1).
(2) If m < 0 (resp. m > 0), then f is increasing (resp. decreasing) on R.
(3) The graph of the function f has a unique inflection point, at
θ := − log(l2 − l1) + p
m
.
Corollary 2.3. The parameter l1 is a solution of the following equation :
(1) log
[
2
f(θ)− f(0)
f(0)− l1 + 1
]
− 2θf
′(θ)
f(θ)− l1 = 0.
Moreover,
l2 = 2f(θ)− l1, m = − 2f
′(θ)
f(θ)− l1 and p = log
[
1
f(0)− l1 −
1
2[f(θ)− l1]
]
.
Proposition 2.4. The logistic function f is the solution of the following ordinary
differential equation :
(2) y(x) = f(0)−m
∫ x
0
[y(u)− l1]
[
1− 1
l2 − l1 [y(u)− l1]
]
du.
Consider n ∈ N∗ observations y1, . . . , yn of the logistic function f at x1 =
0, x2 . . . , xn respectively. The end of the section is devoted to some methods to
approximate the parameters m, p, l1 and l2 of the logistic function f .
On one hand, assume that the values of the parameters l1 and l2 are known. Let
Φ :]l1, l2[→ R be the map defined by :
Φ(x) := log
(
1
x− l1 −
1
l2 − l1
)
; ∀x ∈]l1, l2[.
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By Proposition 2.4 together with the change of variable formula for the Riemann-
Stieljès integral :
Φ[f(x)] = Φ[f(0)] +
∫ x
0
Φ′[f(u)]df(u)
= Φ[f(0)]−
m
∫ x
0
Φ′[f(u)][f(u)− l1]
[
1− 1
l2 − l1 [f(u)− l1]
]
du
= p−mx.
So, if l1 and l2 are known, the parameters m and p can be approximated by linear
regression on (x1, z1), . . . , (xn, zn), where
zi := Φ(yi) ; ∀i ∈ {1, . . . , n}.
Precisely,
m̂n := −
− 1
n− 1
(
n∑
i=1
xi
)(
n∑
i=1
zi
)
+
n∑
i=1
xizi
− 1
n− 1
(
n∑
i=1
xi
)2
+
n∑
i=1
x2i
and
p̂n :=
1
n− 1
n∑
i=1
zi +
m̂n
n− 1
n∑
i=1
xi
are some unbiased estimators of m and p respectively. This method is classic (see
R.F. Gunst and R.L. Mason [6]).
On the other hand, assume that the values of the parameters l1 or l2 are unknown.
In that case, the transformation Φ cannot by applied to y1, . . . , yn. In the current
paper, an alternative method of approximation is provided.
Since card({1, . . . , n− 1}) <∞, the maximization problem
max
i∈{1,...,n−1}
∣∣∣∣ yi+1 − yixi+1 − xi
∣∣∣∣
has a unique solution n(θ). So,
θn :=
xn(θ)+1 + xn(θ)
2
, γn =
yn(θ)+1 + yn(θ)
2
and δn :=
yn(θ)+1 − yn(θ)
xn(θ)+1 − xn(θ)
define some converging approximations of θ, f(θ) and f ′(θ) respectively.
If the value of l1 is known but not the value of l2, then by Corollary 2.3 :
l2(n) := 2γn − l1
defines an approximation of l2. So, the previous method is adaptable by replacing
Φ by the map Φn :]l1, l2(n)[→ R defined by :
Φn(x) := log
[
1
x− l1 −
1
l2(n)− l1
]
; ∀x ∈]l1, l2(n)[.
If the values of l1 and l2 are both unknown, let l1(n) be the numerical approximation
of the solution of the following equation :
(3)
γn − y1
y1 − l1(n) +
1
2
− 1
2
exp
[
2θnδn
γn − l1(n)
]
= 0.
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It defines an approximation of l1 because Equation (3) is a discretization of Equation
(1). Moreover, by Corollary 2.3 :
l2(n) := 2γn−l1(n), mn := − 2δn
γn − l1(n) and pn := log
[
1
y1 − l1(n) −
1
2[γn − l1(n)]
]
define some converging approximations of l2, m and p respectively.
3. A model of the dose-effect relation
The model introduced in this section is tailor-made to study the relation between
a dose d > 0 and a quantitive measure E(d) of an effect of the administered drug.
Precisely, E(d) can be a measure of the therapeutic response or a measure of a
side-effect.
3.1. The skew normal distribution. On the skew normal distribution, see Az-
zalini [2] and Chen et al. [5].
Definition 3.1. The skew normal distribution of parameters ξ ∈ R (location),
ω > 0 (scale) and α ∈ R (shape) is the probability measure Π on (R,B(R)) defined
by :
Π(dx) =
dx
ω
√
2pi
exp
(
−|x− ξ|
2
2ω2
)[
1 + erf
[
α(x− ξ)
ω
√
2
]]
.
The skew normal distribution of parameters ξ, ω and α is denoted by N (ξ, ω2, α).
Consider ξ, α ∈ R and ω > 0. The parameters of the skew normal distribution
N (ξ, ω2, α) are related to its mean µ, its standard deviation σ and to its skewness
coefficient γ (Pearson) as follow :
α =
δ√
1− δ2 , ω
2 =
σ2
1− 2δ2/pi and ξ = µ− ωδ
√
2
pi
with
|δ| := |γ|
1/3
√
pi/2√
|γ|2/3 + [(4− pi)/2]2/3 .
Let (X1, . . . , Xn) be a n-sample (n ∈ N∗) such that X1  N (ξ, ω2, α). Consider
Xn :=
1
n
n∑
i=1
Xi, S2n :=
1
n
n∑
i=1
(Xi −Xn)2 and γ̂n := 1
n
n∑
i=1
(
Xi −Xn
Sn
)3
.
So,
α̂n :=
δ̂n√
1− δ̂2n
, ω̂2n :=
S2n
1− 2δ̂2n/pi
and ξ̂n := Xn − ω̂nδ̂n
√
2
pi
with
|δ̂n| := |γ̂n|
1/3
√
pi/2√
|γ̂n|2/3 + [(4− pi)/2]2/3
are some converging estimators of α, ω2 and ξ respectively.
3.2. The skew normal model of the D-E relation. The model is a family of
random variables E := {E(d), d ∈ R+} satisfying the following assumption :
Assumption 3.2. .
(1) For every d ∈ R+, E(d)  N (ξ(d), ω2(d), α(d)) where ξ, α ∈ C0(R+,R)
and ω ∈ C0(R+, ]0,∞[).
(2) µ : d ∈ R+ 7−→ E[E(d)] is a logistic function.
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(3) There exists d0 ∈ R+ such that σ : d ∈ R+ 7−→
√
var[E(d)] is decreasing on
[d0,∞[, and
lim
d→∞
σ(d) = 0.
Assumption 3.2.(3) means that the variability of the measured effect between
the patients tends to vanish for large doses of the drug.
Assume that E(d) is a measure of the therapeutic response of the administered
drug at the dose d ∈ R+. It is usual to assume that E(d) is a Gaussian random
variable. The skewness of the empirical distributions are taken into account in the
model E of the therapeutic response in order to refine the choice of an optimal
dose. Indeed, the skewness of the distribution of E(d) indicates if the therapeutic
responses of the major part of the patients are over (positive skewness coefficient)
or under (negative skewness coefficient) the mean therapeutic response. Therefore,
if the mean of E(d) is high enough, its skewness coefficient is positive and its stan-
dard deviation is small enough, then the dose d is admissible.
With the notations of Assumption 3.2, the last part of the section deals with the
estimation of the functions µ and σ, and then of the functions ξ, ω and α. So,
for each admissible dose d > 0, Assumption 3.2.(1) allows to simulate the measure
of the therapeutic response E(d) multiple times for a better evaluation at the dose d.
Consider the finite set D ⊂ R+ of the administered doses and, for every d ∈ D,
n ∈ N∗ independent observations e1(d), . . . , en(d) of the random variable E(d). For
each dose d ∈ D, m(d), σ(d) and γ(d) can be estimated by
m̂n(d) :=
1
n
n∑
i=1
ei(d),
σ̂2n(d) :=
1
n
n∑
i=1
[ei(d)− m̂n(d)]2 and
γ̂n(d) :=
1
n
n∑
i=1
[
ei(d)− m̂n(d)
σ̂n(d)
]3
respectively.
Since m is a logistic function by Assumption 3.2, its parameters can be approx-
imated by the method stated at Section 2.
Assume there exists d̂0 ∈ D such that
d ∈ D 7−→ σ̂n(d)
is decreasing on D ∩ [d̂0,∞[.
(1) If the function d ∈ D 7−→ σ̂n(d) is constant on D ∩ [0, d̂0[, then σ could
be a logistic function. Its parameters can be approximated by the method
stated at Section 2.
(2) If the function d ∈ D 7−→ σ̂n(d) is increasing on D∩ [0, d̂0[, then σ could be
a Gaussian-type function :
σ(d) := l + exp(−md2 + pd+ q) ; ∀d ∈ R+
with m > 0 and l, p, q ∈ R. Since
lim
d→∞
σ(d) = 0
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by Assumption 3.2.(4), then l = 0. So, the parameters m, p and q can be
approximated by polynomial regression on {(d, yn(d)); d ∈ D}, where
yn(d) := log[σ̂n(d)] ; ∀d ∈ D.
This method is classic (see P. Armitage et al. [1]).
4. An application to an antidepressant medication
This section deals with a model of the escape time (ET) of rats under an exper-
imental antidepressant (AD) medication. For confidentiality reasons, the name of
the drug is not specified.
The escape time (in seconds) is interpreted as a therapeutic response to the AD.
The AD is administered at four different doses : 0, 0.75, 1.5 and 3 mg.kg−1. The
escape time is evaluated on 32 rats ; 8 rats for each posology.
For each dose, the mean, the standard deviation and the skewness coefficient of
the escape time have been computed :
Statistics | Doses 0 0.75 1.5 3
Mean 33.3875 44.1625 51.5 78.225
Standard deviation 26.9715 30.8113 44.6582 31.9657
Skewness −0.0276 −0.1381 1.2827 0.3504
4.1. The model of the dose-escape time relation. According to Assumption
3.2, the mean escape time is modeled by a logistic function of the administered
dose. By using the approximation procedure stated at Section 2 :
mET(d) = 21.8153 +
1
0.0116 + e−0.8278·d−2.5929
; ∀d ∈ R+.
The standard deviation and the skewness coefficient are modeled by Gaussian type
functions of the administered dose. By using polynomial regressions as suggested
at Section 3 :
σET(d) = exp(−0.1502 · d2 + 0.5289 · d+ 3.2459)
and
γET(d) = 0.2381 + exp(−0.6503 · d2 + 2.2935 · d− 1.5578)
for every d ∈ R+.
The functions mET, σET and γET are plotted on the interval of doses [0, 4] :
Figure 1. Mean ET
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Figure 2. Std. dev. ET Figure 3. Skewness ET
4.2. The optimal dose. The optimal dose should maximise the mean and the
skewness coefficient, and minimize the standard deviation of the therapeutic re-
sponse.
Unfortunately, there is no dose such that these conditions are satisfied together
by the model of the dose-escape time relation.
Consider the dose dopt := 3 which maximizes the mean on [0, 3], and such that
σET(dopt) = 32.4903 and γET(dopt) = 0.3504.
Since the AD tested in the clinical trial has a priori no significant side-effect for
the doses less or equal than 3 mg.kg−1, dopt could be the optimal dose. Indeed, it
maximizes the mean of the escape time, σET(dopt) is closer to
min
d∈[0,3]
σET(d) = 26.9715
than to
max
d∈[0,3]
σET(d) = 44.6582,
and γET(dopt) > 0.
Appendix A. The proofs of Section 2
Proof of Proposition 2.2. For every x ∈ R,
f ′(x) = − me
mx+p
[(l2 − l1)−1 + emx+p]2
and
f ′′(x) = − m
2emx+p
[(l2 − l1)−1 + emx+p]3
(
1
l2 − l1 − e
mx+p
)
.
(1) Assume that m < 0. So,
lim
x→−∞ f(x) = l1 + 0 = l1
and
lim
x→∞ f(x) = l1 +
1
(l2 − l1)−1 = l2.
Assume that m > 0. So,
lim
x→−∞ f(x) = l1 +
1
(l2 − l1)−1 = l2
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and
lim
x→∞ f(x) = l1 + 0 = l1.
(2) If m < 0 (resp. m > 0), f ′(x) > 0 (resp. f ′(x) < 0) for every x ∈ R. So, if
m < 0 (resp. m > 0), then f is increasing (resp. decreasing) on R.
(3) f ′′(x) = 0 if and only if x = θ. Moreover, ifm < 0 (resp. m > 0), f ′′(x) > 0
if and only if x ∈]−∞, θ[ (resp. x ∈]θ,∞[). So, the graph of the function
f has a unique inflection point, at θ.
That achieves the proof. 
Proof of Corollary 2.3. By Definition 2.1 :
(4) f(0) = l1 +
1
(l2 − l1)−1 + ep .
By Proposition 2.2 :
θ = − log(l2 − l1) + p
m
,(5)
f(θ) =
l1 + l2
2
and(6)
f ′(θ) = −m(l2 − l1)
4
.(7)
By Equation (6), l2 = 2f(θ)− l1. By Equation (7) :
(7) ⇐⇒ f ′(θ) = −m
2
[f(θ)− l1]
⇐⇒ m = − 2f
′(θ)
f(θ)− l1 .
By Equation (4), since l2 > f(0) by the definition of f :
(4) ⇐⇒ f(0) = l1 + 1
1/2[f(θ)− l1]−1 + ep
⇐⇒ p = log
[
1
f(0)− l1 −
1
2[f(θ)− l1]
]
.
By Equation (5) :
(5) ⇐⇒ θ = − 1
m
log
[
2
f(θ)− l1
f(0)− l1 − 1
]
⇐⇒ log
[
2
f(θ)− f(0)
f(0)− l1 + 1
]
− 2θf
′(θ)
f(θ)− l1 = 0.
That achieves the proof. 
Proof of Proposition 2.4. For every x ∈ R,
f ′(x) = − me
mx+p
[(l2 − l1)−1 + emx+p]2
= −m
[
l1 +
1
(l2 − l1)−1 + emx+p − l1
]
×[
1− 1
l2 − l1
[
l1 +
1
(l2 − l1)−1 + emx+p − l1
]]
= −m[f(x)− l1]
[
1− 1
l2 − l1 [f(x)− l1]
]
.
So, the logistic function f is the solution of Equation (2). 
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